Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20689441 | 0.96 | OPRM1 (0.49) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL21227592 | 0.91 | TYK2 (0.43) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL20697315 | 0.91 | TYK2 (0.43) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL25069957 | 0.91 | TYK2 (0.43) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL27357534 | 0.89 | TYK2 (0.40) | OPRM1OPRD1OGFRL1ELANEIRAK4 | |
| SCHEMBL20696938 | 0.89 | TYK2 (0.47) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL20697448 | 0.89 | TYK2 (0.47) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL20688549 | 0.89 | TYK2 (0.47) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL20689579 | 0.89 | TYK2 (0.47) | OPRM1OPRD1OGFRL1KMT2AL3MBTL1 | |
| SCHEMBL20689512 | 0.88 | TYK2 (0.42) | OPRM1OPRD1OGFRL1ELANEIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | OPRM1 4673/4885OPRD1 4645/4885OGFRL1 3591/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | OPRM1 4673/4885OPRD1 4645/4885OGFRL1 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.